Informational letter to healthcare professionals on the possible development of hypertriglyceridemia with the use of the medicinal product ALECENSA® (alectinib)

10.02.2026 Updated 11.02.2026 356 views

Інформаційний лист-звернення до спеціалістів системи охорони здоров’я щодо можливості розвитку гіпертригліцеридимії при застосуванні лікарського засобу АЛЕКЕНЗА® ( алектиніб)PDF · 361 КБ

Завантажити

Informational letter to healthcare professionals on the possible development of hypertriglyceridemia with the use of the medicinal product ALECENSA® (alectinib)

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Informational letter to healthcare professionals on the possible development of hypertriglyceridemia with the use of the medicinal product ALECENSA® (alectinib)

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration